Clinical trials traditionally rely only on data from newly enrolled patients. But Bayesian borrowing allows researchers to incorporate external data from past studies to strengthen new trials.

In January 2026, the FDA released draft guidance expanding how sponsors can use external controls and Bayesian methods in clinical trials. This episode explains how Bayesian borrowing works, why it can make trials faster and smaller, and the risks regulators are trying to control.

👉 Enjoyed the episode? Follow the show to get new episodes automatically.

If you found the content helpful, consider leaving a rating or review — it helps support the podcast.

For business and sponsorship inquiries, email us at:
📧 [email protected]

Youtube: https://www.youtube.com/@BJANALYTICS

Instagram: https://www.instagram.com/bjanalyticsconsulting/

Twitter/X: https://x.com/BJANALYTICS

Threads: https://www.threads.com/@bjanalyticsconsulting